Menu
+
+
+
+
+
+
Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from a Phase Ib trial in 30 patients ages 50-75 with knee and/or hip osteoarthritis (OA) showing that three dose levels of once-daily oral GLPG1972 for four weeks were well tolerated. On a secondary endpoint,...
BioCentury employs a fully integrated multimedia platform — including publications, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.
